Peapack Gladstone Financial Corp acquired a new position in Repligen Co. (NASDAQ:RGEN – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,986 shares of the biotechnology company’s stock, valued at approximately $296,000.
Other large investors also recently added to or reduced their stakes in the company. Andra AP fonden purchased a new position in shares of Repligen during the 2nd quarter worth $25,000. International Assets Investment Management LLC bought a new position in Repligen in the 2nd quarter worth $33,000. UMB Bank n.a. lifted its position in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. grew its holdings in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 127 shares during the period. Finally, Resources Management Corp CT ADV purchased a new stake in Repligen in the third quarter worth about $37,000. 97.64% of the stock is currently owned by institutional investors.
Repligen Stock Performance
NASDAQ:RGEN opened at $160.92 on Tuesday. The company has a market cap of $9.02 billion, a price-to-earnings ratio of -434.92, a PEG ratio of 4.64 and a beta of 0.96. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $211.13. The stock’s 50 day simple moving average is $142.66 and its two-hundred day simple moving average is $141.59. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76.
Wall Street Analyst Weigh In
RGEN has been the subject of a number of recent research reports. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They set an “overweight” rating and a $180.00 price objective for the company. StockNews.com upgraded shares of Repligen from a “sell” rating to a “hold” rating in a research report on Friday, November 22nd. Wolfe Research began coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $190.25.
Read Our Latest Analysis on Repligen
Repligen Company Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
- Five stocks we like better than Repligen
- What is Insider Trading? What You Can Learn from Insider Trading
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
- 5 Top Rated Dividend Stocks to Consider
- 3 Companies Leading the Way With Aggressive Stock Buybacks
- How to Evaluate a Stock Before Buying
- Is It Time to Buy Nuclear Energy Stocks After the Latest Dip?
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.